Wednesday, 15 Aug 2018

You are here

Back Pain in Psoriatic Arthritis

A single center study of psoriatic arthritis patients has shown that rheumatologist-judged inflammatory back pain (IBP) and criteria defining IBP may not perform well when ascertaining axial involvement in PsA patients. 

Using prospective clinic data and clinical assessments in a cohort of PsA patients, 171 patients (52% male, mean age 46.6 years) were studied. More than half (56%) reported chronic back pain.  Inflammatory back was either rheumatologist defined or defined by one of 3 accepted criteria for IBP (Calin, Rudwaleit, ASAS).

Inflammatory back pain was seen in 38% of patients and 32% had evidence of radiological changes in the spine.

The agreement between rheumatologist judgement of IBP and criteria used for IBP was highest for the Calin criteria (0.70).

Rudwaleit criteria for IBP (2.17) had the highest positive likelihood ratio for radiological axial involvement.

Amongst AxPsA with or without back pain, those with back pain had higher BASDAI scores and lower frequency of HLA-B*38 .

IBP as judged by the rheumatologist does not always agree with IBP criteria, nor will all have xrays changes of spondylitis.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Minimal Disease Activity: The Goal in PsA

The majority of patients with psoriatic arthritis (PsA) who achieved a state of minimal disease activity (MDA) after 6 months of treatment with adalimumab (Humira) maintained that response through 24 months, a large observational study found.

Liver Disease Increased in Psoriasis

An observational case-control study has shown that psoriasis is associated with an increased prevalence of nonalcoholic fatty liver disease (NAFLD).

A single center, outpatient dermatology clinic studied 151 patients with psoriasis and 51 control subjects with ultrasonography to diagnose NAFLD.

Best of 2017: Cause of Death in Ankylosing Spondylitis

A French population based study of ankylosing spondylitis (AS) was report in the Journal of Rheumatology.

They analyzed the death certificates and cause of death in 2940 AS patients over 3 different decades (1969-78; 1979-99; 2000-2009).

The mortality rate of AS remained stable over time.

Ixekizumab Effective in Ankylosing Spondylitis

Eli Lilly announced today the results of the COAST-W trial showing that ixekizumab (Taltz) was effective in a Phase 3 study Ankylosing Spondylitis (AS) patients who had an inadequate response or intolerance to tumor necrosis factor (TNFi) inhibitor therapy.

NPF Dietary Recommendations for Psoriatic Disease

The National Psoriasis Foundation has released dietary recommendations for adults with psoriasis and psoriatic arthritis, based on a systematic review of the current literature, with the strongest focus on weight reduction for those who are overweight or obese.